Advertisement Winston receives SBIR grant to develop postherpetic neuralgia therapy - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
11 Apr 2012
News

Winston receives SBIR grant to develop postherpetic neuralgia therapy

By PBR Staff Writer
Continue reading

Winston Pharmaceuticals has received a small business innovation research (SBIR) grant from the National Institutes of Health for the development of Civamide to treat postherpetic neuralgia (PHN) of the trigeminal nerve (TN).

The Phase I award worth $375,000 will be directed by the National Institute of Neurological Disorders and Stroke.

Winston president and CEO Joel Bernstein said the use of TRPV-1 modulators in treating neuropathic disease is a unique approach in the area, and the SBIR grant gives an opportunity to further investigate the use of this class of medications.

"The availability of an effective and safe treatment, i.e., without systemic effects or drug interactions, would fill an important unmet medical need in the treatment of PHN of the TN," Bernstein added.